Company intelligence / Profile preview

Talis Biomedical

Chicago, Illinois, United Statestalisbio.com ↗

Ownership: Public · TLIS
Development stage: Preclinical

Overview

Talis Biomedical has developed and commercialized the Talis One™ system, a rapid point-of-care molecular diagnostic device designed to deliver lab-quality results for infectious disease testing in under 30 minutes. The company’s focus has been on enabling accurate and timely diagnosis at the point of care to improve health outcomes and equity

Therapeutic areas: Infectious Diseases
Modalities: Device
Industry: Molecular Diagnostics

Drug pipeline

1 asset

Talis One

Pre-clinical

Indications: Infectious diseases

Financials

Market cap: $5.2M
Total revenue: $0
Enterprise value: $-35.9M

Beyond the preview

Go deeper on Talis Biomedical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Talis Biomedical.

Explore the full profile